Statistics for Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting
Total visits
| views | |
|---|---|
| Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting | 73 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| muntanola-cts-safe.pdf(legacy) | 64 |
| muntanola-cts-safe.pdf | 42 |
Top country views
| views | |
|---|---|
| United States | 62 |
| Ireland | 8 |
| Belgium | 1 |
| South Korea | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Fremont | 10 |
| Mountain View | 9 |
| Boardman | 8 |
| Ann Arbor | 6 |
| Dublin | 6 |
| Fairfield | 5 |
| Andover | 2 |
| Menlo Park | 2 |
| San Diego | 2 |
| Ashburn | 1 |
| Cambridge | 1 |
| Cedar Creek | 1 |
| Cupertino | 1 |
| Seattle | 1 |
| Shah Alam | 1 |
| Tustin | 1 |